Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00181922 · ClinicalTrials.gov registry record · Phase 4

Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

A Phase 4 study of Bipolar Disorder and Mania, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
2
Study locations

NCT00181922: Completed Phase 4 study of Bipolar Disorder and Mania, sponsored by Massachusetts General Hospital.

NCT00181922 is a Phase 4 study of Bipolar Disorder and Mania that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00181922, a Phase 4 study of Bipolar Disorder and Mania, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The objective of this study is to compare the safety and effectiveness of Ziprasidone in the treatment of mania in children and adolescents with Bipolar disorder over 8 weeks. This is an exploratory, open-label study, which seeks to determine if there is evidence for efficacy. The results of this study will be used to generate hypotheses for a larger study.

Conditions Studied

Bipolar Disorder Mania

Interventions

  • DRUG ziprasidone (Geodon)

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Massachusetts General Hospital - Cambridge

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2002-03
Est. Completion 2004-12
Phase Phase 4
Massachusetts General Hospital

2,032 total trials

What the finished NCT00181922 record still lists

NCT00181922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which ziprasidone (Geodon) is the first listed.

NCT00181922 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00181922 about?

NCT00181922 is a clinical study titled "Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder". The objective of this study is to compare the safety and effectiveness of Ziprasidone in the treatment of mania in children and adolescents with Bipolar disorder over 8 weeks. This is an exploratory, open-label study, which seeks to determine if there is evidence for efficacy. The results of this st...

What is the current status of trial NCT00181922?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2002-03. Estimated completion is 2004-12.

What conditions does trial NCT00181922 study?

This clinical trial studies the following conditions: Bipolar Disorder, Mania.

What interventions are being tested in trial NCT00181922?

The interventions under investigation include: ziprasidone (Geodon) (DRUG).

Who is sponsoring clinical trial NCT00181922?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00181922 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00181922's enrollment target sits among peer trials

20 154th of 162 higher than 6 of 162 other Bipolar Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00181922, the US trial registry maintained by the National Library of Medicine. NCT00181922 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.